The week of April 14 brought two seismic regulatory developments that every practice billing Medicaid or dealing with drug prior authorization must now track closely.
CMS released the “2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule” (CMS-0062-P) on April 14 — the most significant new rulemaking of the week. This rule extends the CMS-0057-F framework specifically to drug prior authorization, requiring impacted payers (Medicare Advantage, Medicaid, CHIP, and QHP issuers on the FFE) to support electronic prior authorization for drugs via updated FHIR-based APIs beginning October 1, 2027.
The “One Big Beautiful Bill Act” is signed into law, restructuring Medicaid with direct implications for practice eligibility workflows. States must implement community engagement (work) requirements of 80 hours/month for Medicaid expansion adults by December 31, 2026. States must conduct eligibility redeterminations every 6 months (replacing annual renewals). HHS implementation guidance is due to states by June 1, 2026, with state enrollee outreach required between June 30–August 31, 2026. An estimated 4.8 million Americans could lose coverage from work requirements alone.
The 2026 PFS conversion factors remain live: $33.5675 for APM-qualifying physicians and $33.4009 for all others. The structural shift practices must internalize: facility-based physician payments fell approximately 7% while independent office-based service payments rose approximately 4% — a deliberate CMS rebalancing that rewards care delivered in independent physician offices rather than hospital outpatient settings.
The H.R. 1 eligibility changes will trigger a wave of Medicaid coverage churn starting Q3 2026. Practices serving Medicaid populations must upgrade eligibility verification to real-time, automated daily checks. A manual verification workflow at check-in will fail to keep pace with six-month redetermination cycles — and unverified coverage at the point of service is the leading driver of Medicaid claim denials.
Despite voluntary reform commitments from more than 50 health plans, the Medicare Advantage prior authorization crisis is worsening. The data from the first quarter of 2026 tells a troubling story — and the new CMS-0062-P proposed rule is a direct regulatory response to these numbers.
The KFF finding that 80.7% of appealed MA PA denials are ultimately overturned is one of the most consequential statistics in RCM today. It means that for every five MA PA denials your practice receives, four are statistically likely to be collectible — but only if your team has the bandwidth to file a formal appeal. Administrative rework costs $47 per MA claim. Denial volumes are being driven by a nearly fivefold increase in Request for Information (RFI) and medical necessity denials at the plan level.
| Payer | 2026 Reform Action | Impact for Practices |
|---|---|---|
| UnitedHealthcare | Dropped PA for 231 procedures (nuclear medicine, OB ultrasounds, ECGs) | Reduced pre-auth burden for cardiology, OB, and diagnostic practices |
| Cigna | Eliminated PA for ~100 services; added real-time PA status tools | Faster approvals; significantly less phone-based follow-up |
| Aetna | Bundled medical procedure + pharmaceutical PA into single submission | Eliminates double-submission for procedure + drug combinations |
| All 50+ Plans | Honor existing authorizations for 90-day transition when patient switches insurer | Protects continuity-of-care billing during mid-year insurance transitions |
Despite these commitments, MA PA denial rates are still up 56% — signaling meaningful implementation gaps between policy announcements and operational execution at the plan level. CMS is accelerating regulatory response with CMS-0062-P.
CMS announced expansion of its MA audit program from approximately 60 plans per year to all 550 eligible MA contracts annually, and is clearing a backlog of 2018–2024 audits. Practices should anticipate increased payer scrutiny on risk adjustment documentation and prior authorization accuracy as plan-level enforcement tightens.
Practices accepting Medicare Advantage must treat denial management as a permanent, dedicated workflow — not an occasional task. At $47 per rework event and an 80.7% appeal reversal rate, every appealed denial has a statistically positive expected value. The constraint is staff bandwidth, not merit. If you do not have a named denial follow-up owner and a 30-day aging dashboard, assign both today.
The debate over ambient AI scribes moved definitively into evidence territory this week. A landmark study published April 1, 2026 covering 1,800 clinicians across five academic medical centers (2023–2025) quantified the effect of ambient AI documentation on physician time, clinical output, and downstream RCM performance — with results that every practice evaluating AI should now be citing in their business case.
The multi-site study across five academic medical centers found ambient AI scribe users saved 16 minutes of documentation time and spent 13 fewer minutes in the medical record per 8-hour shift. Results varied by product: Nabla users saw a 9.5% decrease in time-in-note vs. control; DAX Copilot showed no significant change (-1.7%). The RCM-relevant finding is upstream: Riverside Health (Virginia) reported an 11% rise in physician wRVUs and a 14% increase in documented HCC diagnoses per encounter after ambient AI deployment. A 2024 Texas Oncology study found ambient scribes increased documented diagnoses from 3.0 to 4.1 per encounter — directly improving coding completeness and reimbursement.
Per the 2026 Guidehouse/HFMA RCM Trends survey, 78% of healthcare executives are using automation and AI to accelerate manual revenue cycle processes. Per Revele’s Spring 2026 industry brief, 53% of healthcare organizations have adopted agentic AI or multi-agent workflows — up dramatically from pilot-stage use in 2024. Early adopters report: denial rate reductions of 30–50%, prior authorization times dropping from days to hours, clean claim rate improvements of 15–30%, and Days in A/R declining 20–35%.
Over 30% of U.S. healthcare organizations are adopting or actively considering fully autonomous coding — systems that assign, validate, and submit codes without manual intervention. AI-driven coding systems reduce coding time by 40% and increase accuracy to 95%+. The market pressure is real: 60% of RCM leaders cite finding ICD-11-ready certified coders as their primary staffing hurdle, and manual-only operations now carry a 45-day average backlog in unbilled charts.
An 11% wRVU increase and 14% more HCCs documented per encounter translate directly into billing revenue. For a physician generating $400,000/year in Medicare RVU-based payments, an 11% lift represents approximately $44,000 in additional annual revenue — before accounting for any improvement in coding accuracy or denial reduction. This is no longer a technology investment story; it is a revenue recovery story.
While the April 1 ICD-10-CM instructional note updates were covered in last week’s issue, several January 1 CPT code changes are now surfacing in real-world billing workflows and warrant immediate attention. The 2026 CPT code set includes 418 total changes (288 new codes, 84 deletions, 46 revisions) — the largest overhaul in recent memory. Practices that have not completed a full superbill audit are at claims risk.
New permanent Category I code 75577 covers AI-enhanced CT coronary angiography plaque quantification. This converts AI-assisted cardiac imaging analysis from an overhead cost into a directly revenue-generating billable service. New Category III codes 0992T and 0993T cover cardiac risk assessment via algorithmic perivascular fat analysis. Cardiology and radiology practices using AI-assisted coronary CT tools must map their clinical workflows to these codes immediately or leave revenue uncaptured.
New 2026 CPT codes now cover 2–15 days of remote patient monitoring (RPM) and remote therapeutic monitoring (RTM) transmitted data. The existing codes — 99454 for RPM; 98976–98978 for RTM — now apply exclusively to 16–30 days of data. Practices billing RPM or RTM must update billing logic: patients with fewer than 16 days of transmitted data require the new short-cycle codes. Claims filed under the wrong code will be denied or downcoded.
| Code Type | 2026 Change | Billing Action Required |
|---|---|---|
| CPT 75577 | New permanent code — AI-enhanced CT CA plaque quantification | Map AI cardiac CT workflows; bill directly for eligible patients |
| 0992T / 0993T | New Category III — cardiac risk assessment, algorithmic perivascular fat analysis | Verify payer coverage; begin tracking eligible encounters |
| RPM / RTM short-cycle | New codes for 2–15 days of transmitted data | Update billing logic; existing codes (99454, 98976–98978) now = 16–30 days only |
| GI Endoscopic Sleeve Gastroplasty | New permanent code for bariatric endoscopy procedure | Add to GI superbill; verify payer coverage policies |
| X461T–X466T / X504T | New Category III — continuous EEG monitoring; AI EEG waveform analysis | Evaluate adoption for neurology centers performing continuous EEG monitoring |
Practices that have not audited their superbills and billing software against the full 2026 CPT update are at risk of submitting claims under deleted or revised codes. A claim filed under a deleted CPT code will be rejected by every payer. Conduct a full audit of your top 30 procedure codes against the 2026 CPT code set before the end of April — prioritize RPM/RTM split logic, cardiology AI codes, oncology radiation therapy codes, and GI endoscopy unbundling rules.
The Medicare Advantage denial burden is now a quantifiable line item eroding practice revenue. With $47 in administrative cost per reworked MA claim and denial rates exceeding 17%, the math reveals a hidden revenue drain that compounds every month your team does not have a dedicated denial management workflow.
| Scenario | Detail | Annual Cost |
|---|---|---|
| 1,000 MA claims/month | 17% denial rate = 170 denials/month × $47 rework cost | $95,880/year in direct rework cost |
| Staff labor (80.7% appealed) | 137 appeals/month × 2 hrs × $25/hr | $82,200/year in staff time |
| Combined burden | Rework + labor (before recovery) | $178,080/year hidden MA denial tax |
| KPI | Industry Average | Best Practice Target | High-Risk Threshold |
|---|---|---|---|
| Denial Rate | 6–13% | < 5% | > 15% |
| Days in A/R | 33–42 days | < 30 days | > 50 days |
| Clean Claim Rate | ~85% | 95–98%+ | < 80% |
| Net Collection Rate | ~92% | > 95% | < 90% |
| First-Pass Acceptance Rate | ~80% | > 85% | < 75% |
A practice with $5M in annual charges, a 12% denial rate, and 45 days in A/R could recover $300,000–$500,000 annually by reaching industry best-practice targets. The ROI on denial management automation and real-time eligibility is rarely negative — and in 2026, the tools to achieve it are more accessible than ever.
The RCM technology market is moving fast in April 2026, with a landmark acquisition in progress, the FHIR API compliance deadline now under 9 months away, and the ambient AI vendor landscape maturing rapidly.
India-based health IT and RCM firm IKS Health (Inventurus Knowledge Solutions) is nearing a deal to acquire Nasdaq-listed TruBridge for approximately $600 million, financed by a $675M debt facility from Citi, Deutsche Bank, and JP Morgan (reported April 13, 2026). TruBridge serves approximately 700 community hospitals primarily in the Southeast and rural Midwest. This is IKS’s largest acquisition to date, targeting the community hospital and rural/mid-size provider RCM segment that has historically been underserved by enterprise platforms. The deal signals continued consolidation in outsourced RCM: IKS brings offshore AI-driven coding and automation capacity; TruBridge brings a large installed base of mid-size provider EHR and billing clients.
The CMS-0057-F Prior Authorization API deadline is January 1, 2027. Impacted payers must implement four FHIR R4 APIs: Patient Access, Provider Access, Payer-to-Payer, and Prior Authorization. For practices, the action is vendor confirmation: Epic, Cerner, eClinicalWorks, and Athenahealth all support FHIR R4 access, but PM/EHR configuration and payer-specific endpoint setup requires practice-side action. The new CMS-0062-P drug PA rule extends FHIR requirements to pharmaceutical PA by October 2027 — making FHIR integration a two-phase, multi-year compliance project.
Practices evaluating RCM technology in Q2 2026 should prioritize vendors with documented FHIR R4 API roadmaps and confirmed CMS-0057-F compliance timelines. Any vendor that cannot confirm January 2027 FHIR readiness today will become a workflow bottleneck at the worst possible time. Require written FHIR roadmap documentation as a procurement standard item this quarter.
Three compliance priorities converge in Q2 2026. Each carries material legal and financial risk for non-compliant practices.
The 2026 HIPAA Security Rule update introduced mandatory security controls that are in effect now:
OCR HIPAA penalties averaged $6.6 million total across 2025 enforcement actions and are rising. Practices that have not implemented MFA across all PHI access systems are out of compliance today.
CMS is auditing all 550 eligible MA contracts annually, up from approximately 60 per year, and is clearing a backlog of audits from 2018–2024. This intensifies MA payer scrutiny on risk adjustment documentation, PA practices, and claim accuracy — creating downstream compliance pressure for practices submitting claims to MA plans. Expect increased requests for clinical documentation to support MA risk adjustment submissions.
With H.R. 1 requiring 6-month eligibility redeterminations for Medicaid expansion adults starting Q3–Q4 2026, practices serving Medicaid populations face a coverage verification challenge unlike anything since the post-COVID unwinding. Manual eligibility checks at check-in will not be sufficient. Real-time automated eligibility verification before every encounter is the only sustainable approach at scale.
Assign a HIPAA Security Rule compliance owner before May 1. Audit all PHI access points (EHR, clearinghouse portal, billing software, patient portal, email) for MFA compliance status. Confirm encryption at rest and in transit with your IT vendor. Simultaneously, contact your clearinghouse or PM vendor about automated real-time Medicaid eligibility verification before the H.R. 1 implementation window opens in Q3.
The latest AMA data confirms the long-running consolidation trend continued through 2024: just 42.2% of physicians worked in private practices (down from 60.1% in 2012). 34.5% worked in hospital-owned settings and 6.5% reported private-equity ownership. The 2026 budget environment — flat-to-declining Medicare rates, H.R. 1 Medicaid cuts, rising operational costs — will intensify this pressure further.
Thousands of primary care practices facing financial distress are joining Independent Physician Associations (IPAs) to gain payer negotiating leverage, access value-based care contracts, and maintain independence. NPR (February 2026) reported this as a direct response to Medicaid cuts and commercial rate pressure. Bain & Company’s Global Healthcare Private Equity Report 2026 notes the industry has shifted “from raw consolidation to an era where operational excellence is the only way to win.”
The new voluntary LEAD APM model offers independent primary care practices a sustainable alternative to selling or merging: a 10-year performance period with no ratchet effect, a Professional Risk Option capping downside at 50%, and access to the APM conversion factor of $33.57. The RFA is open now. Independent primary care practices should evaluate LEAD APM participation before the enrollment window closes — this is a rare long-term value-based contract designed specifically for independent practices.
| Metric | Where Most Practices Are | Where You Should Be | Priority |
|---|---|---|---|
| Denial Rate | 10–15% | < 7% | HIGH |
| Days in A/R | 40–55 days | < 35 days | HIGH |
| Clean Claim Rate | 78–84% | > 92% | HIGH |
| Telehealth Billing | Ad hoc or incomplete workflows | Permanent workflows in place | HIGH |
| PA Time per Week | 14–18 hours | < 8 hours (with automation) | MEDIUM |
| Patient Collection Rate | 55–65% | > 75% | MEDIUM |
| AI Tool Adoption | < 20% of workflows | 50%+ of routine workflows | MEDIUM |
68% of physicians now use AI tools in practice, up from 38% in 2023. Independent practices that have not adopted AI-assisted documentation, coding, or eligibility verification are no longer early adopters who missed a trend — they are operationally behind. The performance gap between AI-adopting and non-adopting practices is widening every quarter, and it shows up directly in Days in A/R and net collection rate.
Specialty-specific reimbursement pressures diverge sharply in Q2 2026. Oncology faces the most significant acute impact with drug pricing model changes; cardiology has a mandatory new payment model on the horizon; mental health has rare multi-year billing stability.
| Specialty | Key Q2 2026 Update | Financial Impact | Recommended Action |
|---|---|---|---|
| Primary Care | APCM add-on codes allow APCM + BHI/CoCM in same month; E/M codes exempt from 2.5% cut; LEAD APM RFA open now | Neutral to positive; CCM, TCM, and APCM generate protected revenue streams | Enroll eligible patients in APCM; evaluate LEAD APM participation before window closes |
| Cardiology | CPT 75577 (AI-enhanced CT CA plaque) billable; CMS releases preliminary ASM participant list in July 2026 — ~8,600 physicians face mandatory ±9–12% payment adjustment | Revenue opportunity from AI cardiac codes; mandatory ASM model creates financial risk or reward by performance | Map AI cardiac CT workflows to CPT 75577 now; prepare for July ASM participant list; model ASM financial impact |
| Orthopedics | Mandatory TEAM bundled payment model (30-day surgical episode); ASM targets orthopedic surgery/spine/pain with ±9% payment adjustments; 2.5% efficiency cut on all surgical codes | Bundled episode model adds shared-savings/risk complexity; surgical cuts reduce baseline reimbursement | Audit TEAM model episode definitions; build episode cost management workflows; accelerate modifier/documentation specificity |
| Oncology | GLOBE/GUARD drug pricing models slash ibrutinib reimbursement 38%; 37% of oncologists face Medicare cuts of 10–20%; radiation therapy codes (77402/77407/77412) converted to Levels 1/2/3; IMRT codes 77385/77386 deleted | Significant per-drug revenue compression; IMRT code deletion creates immediate billing risk | Update drug administration billing for GLOBE/GUARD pricing now; remap IMRT claims to new three-level framework; audit all high-cost drug codes |
| Neurology | Claim denial rate averages 18% — 3× industry average; new X461T–X466T continuous EEG codes; X504T AI EEG analysis; NCCI bundling scrutiny on EMG/EEG intensifying | High denial rate represents recoverable revenue; AI EEG codes create new billing pathway at tertiary centers | Build neurology-specific denial work queue; audit EMG/EEG coding against NCCI edits; evaluate X461T–X466T adoption |
| Mental Health | Telehealth extended through December 31, 2027 (CAA 2026); home-based at non-facility rates; audio-only parity; new remote behavioral monitoring codes for 2–15-day cycles; MHPAEA parity audits increasing | Multi-year billing stability rare in 2026 landscape; remote monitoring opens new revenue stream; MHPAEA audit risk rising | Establish permanent tele-mental health workflows; activate remote behavioral monitoring billing; document MHPAEA comparative analyses proactively |
| Gastroenterology | New permanent CPT for endoscopic sleeve gastroplasty; two new anorectal physiology codes; 2.5% efficiency cut on endoscopy; office-based GI payments increase vs. ASC/hospital cuts | Office-based GI advantaged vs. hospital-based settings; bariatric endoscopy new billable code | Add endoscopic sleeve gastroplasty to superbill; evaluate shift of eligible procedures to office setting; update X-modifier vs. modifier 59 workflows by payer |
Oncology practices must act immediately on GLOBE/GUARD drug pricing changes. Ibrutinib reimbursement is reduced 38% starting this month. Any practice billing ASP-based drug administration codes for GLOBE/GUARD-affected drugs without updating unit pricing is either over-billing (fraud risk) or under-billing (revenue loss). Contact your specialty pharmacy partner for a complete list of affected drugs and update billing system pricing before submitting additional claims.
Tied directly to this issue’s content — prioritized by urgency and revenue impact: